Biotech News
Related news
MNKDMannKind2026-06-03 10:05 EST
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MNKDMannKind2026-07-29 10:30 EST
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MISTMilestone Pharmaceuticals Inc.2026-09-24 12:00 EST
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
MLYSMineralys Therapeutics2026-09-23 20:05 EST
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
ALGSAligos Therapeutics2026-08-12 20:05 EST
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
ALGSAligos Therapeutics2026-07-13 12:00 EST
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
RYTMRhythm Pharmaceuticals2026-07-08 21:07 EST
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
ALTAltimmune2026-08-03 12:00 EST
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
LXRXLexicon Pharmaceuticals2026-08-24 12:30 EST
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
MLYSMineralys Therapeutics2026-05-30 15:15 EST
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-09 10:30 EST
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
MNKDMannKind2026-09-02 12:30 EST
MannKind to Present at Upcoming Investor Conferences
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
Stock data
- Close
- 3.95 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States